FAQ on Kairos Pharma Ltd.'s DoD Grant for Lung Cancer Biomarker Research
Summary
What is the purpose of the DoD grant awarded to Kairos Pharma Ltd.?
The $876,000 grant from the U.S. Department of Defense supports biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer, focusing on patients developing resistance to osimertinib.
Why is this research significant?
This research aims to identify patients who may benefit from early intervention with ENV105, potentially improving long-term outcomes through targeted therapy and precision monitoring in non-small cell lung cancer.
How does ENV105 work in treating cancer?
ENV105 is an antibody that targets CD105, a protein linked to resistance in various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Who is conducting the research supported by the DoD grant?
The research is being conducted in Dr. Neil Bhowmick’s lab at Cedars-Sinai Medical Center, in alignment with Kairos’ strategy to advance cancer treatment.
Where can I find more information about Kairos Pharma Ltd.?
More information about Kairos Pharma Ltd. is available on their website at www.KairosPharma.com.
What are the current clinical trials involving ENV105?
ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs.
How can investors stay updated on Kairos Pharma Ltd.?
Investors can find the latest news and updates relating to Kairos Pharma Ltd. (KAPA) in the company’s newsroom at https://ibn.fm/KAPA.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119093